F061 Vascular Anomalies: Classification, Clinical Challenges, and Management Update
DESCRIPTION
Dermatologists play a primary role in diagnosing and directing the management of vascular anomalies. Over the last decade there have been significant developments in the understanding of the pathogenesis of vascular anomalies which have impacted clinical practice. In this session, experts in the field will discuss key topics and literature relating to the evaluation and management of problematic infantile hemangiomas, capillary malformations and vascular anomalies.
LEARNING OBJECTIVES
Examine published data from last year on management of infantile hemangiomas and vascular anomalies
Develop tools for laser therapy and medical management of infantile hemangiomas and vascular anomalies
Review diagnostic criteria and imaging of high risk infantile hemangiomas and vascular anomalies.
SCHEDULE
3:30 PM
Hemangioma Hot Topics
Christine T Lauren, MD, FAAD
3:50 PM
Use of corticosteroids for infantile hemangiomas: Back to the Future
Ilona J. Frieden, MD, FAAD
4:10 PM
Future Directions for the Management of PHACE syndrome: Lessons learned from 1996-2026
Dawn H. Siegel, MD, FAAD
4:30 PM
Future directions for laser surgery of vascular anomalies
Deepti Gupta, MD
4:50 PM
The Future Is Now: Merging Old-School Physical Exams with Cutting-Edge Molecular Diagnostics to Advance Care for Patients with Vascular Anomalies
Beth Ann Drolet, MD, FAAD
5:15 PM
Challenging vascular anomaly cases
DIRECTOR
Dawn H. Siegel, MD, FAAD
SPEAKERS
Beth Ann Drolet, MD, FAAD
Ilona J. Frieden, MD, FAAD
Deepti Gupta, MD
Christine T Lauren, MD, FAAD
DISCLOSURES
Beth Ann Drolet, MD, FAAD
Arkayli Biosciences – Founder(Stock);
Ilona J. Frieden, MD, FAAD
Palvella Therapeutics – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Data Safety Monitoring Board(Fees); Pierre Fabre Dermatologie – Consultant (1099 relationship)(Honoraria);
Deepti Gupta, MD
No financial relationships exist with ineligible companies.
Christine T Lauren, MD, FAAD
No financial relationships exist with ineligible companies.
Dawn H. Siegel, MD, FAAD
No financial relationships exist with ineligible companies.